CompletedNCT00992407
Long-acting injection or tablets of risperidone for schizophrenia
About this title
Read the official source — NCT00992407Medication studyAges 18–55South Korea
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- AnsanSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 75
- Sponsor
- Janssen Korea, Ltd., Korea
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- South Korea
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00992407
- Official title
Show the full official title
A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedAnsan
Questions about this study
Who is behind this study?
The study sponsor is Janssen Korea, Ltd., Korea.
Did this study involve medication?
Yes. The study involved medication, including Risperidone long acting injectables and Risperidone tablets.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
